Navigation Links
New Data Shows Once a Day Lamictal XR is Effective in Treating,Patients with Partial Seizures

Data Presented at the American Academy of Neurology Annual Meeting Show Approximately 50 Percent Reduction in Partial Seizures

BOSTON, May 01, 2007 /PRNewswire/ -- Data from two clinical trials presented today at the American Academy of Neurology (AAN) meeting suggest that an investigational once daily extended release formulation of Lamictal(R) (lamotrigine) is effective as add-on treatment in patients with partial epilepsy with and without secondary generalization. Lamictal XR Extended- Release Tablets are currently in development for the treatment of epilepsy. If approved, it will be the first extended release, new generation epilepsy treatment taken once-daily.

Data from the ARMOR study, an international, multi-center, randomized, double-blind, placebo-controlled trial, showed that the new once-daily, extended release formulation reduced partial seizures by 46 percent, while patients taking placebo experienced a reduction of 24 percent over the entire 19-week treatment period. The study also showed significant overall reduction in seizure frequency in both the escalation and maintenance treatment phases. In addition, the study showed that 42 percent of patients treated with Lamictal XR reduced their frequency of seizures by at least half by the end of the 19-week treatment period.

The second study, COMPASS, showed that patients could be switched from Lamictal(R) immediate release (IR) to Lamictal XR while maintaining comparable blood levels of lamotrigine.

"These data are important because they show that the extended release formulation of Lamictal reduces the frequency of seizures. The once daily dosing regimen may also provide a more convenient treatment option for patients," said Dean Naritoku, M.D., Professor of Neurology and Pharmacology, Southern Illinois University, Springfield, IL. "In addition, when compared to Lamictal immediate release, given twice a day, the new investigatio
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
2. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
5. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
6. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
7. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
8. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
11. New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging
Post Your Comments:
(Date:5/23/2013)... 2013  Echo Pharma Acquisition Limited ("Royalty Pharma") announced ... Acceptance Threshold from 90 percent to 50 percent of ... accordance with the terms of the Revised Offer Document ... Under the terms of the Increased Offer, Royalty ... ELN ) for $12.50 per share in cash. The ...
(Date:5/23/2013)... 2013   BioLife Solutions , Inc. (OTC:BLFS), a ... hypothermic storage and cryopreservation freeze ... media manufacturer , today announced its participation at the ... 2013 this week in London ... Dr. Aby J. Mathew, BioLife,s Senior Vice President and ...
(Date:5/23/2013)... PARIS , May 23, 2013  Volcano ... and manufacturer of precision guided therapy tools designed to ... vascular disease, today announced preliminary results from the ADVISE ... S tenosis E valuation) II trial during ... EuroPCR 2013. These prospective results confirm prior retrospective publications, ...
Breaking Medicine Technology:Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 2Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 3Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 4Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 5Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 6Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 7Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 8Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 9Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 10BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 2BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 3Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 2Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 3Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 4Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 5
... N.J., Aug. 31 QRxPharma (ASX: QRX and OTCQX: ... the 13th World Congress of Pain on 31 August, ... titled "Dual Opioid Therapy: Changing the Paradigm" will focus ... Dual Opioid product for moderate to severe acute pain. ...
... PHILADELPHIA, Aug. 31 Shire plc (LSE: ... biopharmaceutical company, today announced its support for inflammatory bowel ... country.  The six fellowships will begin in 2011 and ... of IBD to physicians who recently completed a fellowship ...
Cached Medicine Technology:QRxPharma to Sponsor Symposium at 13th World Congress on Pain Meeting 2QRxPharma to Sponsor Symposium at 13th World Congress on Pain Meeting 3Shire Announces Support for Inflammatory Bowel Disease (IBD) Fellowships at Leading Medical Institutions Nationwide 2Shire Announces Support for Inflammatory Bowel Disease (IBD) Fellowships at Leading Medical Institutions Nationwide 3
(Date:5/23/2013)... Spring and summer have always been motivation for people ... the city between Memphis and Nashville? In the last year ... has transformed the growing area into one of the most ... of vibrant, young professionals you are going to see demand ... owner of The Fight Shop, one of the city’s hottest ...
(Date:5/23/2013)... Jeanne Ettelson, president of Beyond ... and only free OCD support group in Chicago. ... OCD sufferers, the group is lead by psychologists who ... This allows group participants to learn accurate information about ... , “Participants in Beyond OCD’s support group benefit ...
(Date:5/23/2013)... CA (PRWEB) May 23, 2013 EnvirOasis, ... the contractor and ESCO market is pleased to announce ... Consortium (DLC) Listed LED products. EnvirOasis has been ... fixtures and retrofit kits and has recently brought ... LED (Light Emitting Diode) is energy efficient lighting ...
(Date:5/23/2013)... Symptoms of borderline personality disorder often mimic traits ... But researchers in Canada say they have identified ... personality disorder: a tendency to misinterpret emotions expressed ... processing facial emotions and will see a negative ... a clinical neuropsychologist and assistant professor at the ...
(Date:5/23/2013)... A shortage of a critical tuberculosis drug has hampered ... to contain the spread of the highly infectious lung ... was first used in 1951 and is one of ... first-line treatment for tuberculosis (TB). Patients must take the ... U.S. Centers for Disease Control and Prevention. However, ...
Breaking Medicine News(10 mins):Health News:Grass Roots Wellness Initiative Builds Muscle in Jackson, Tennessee 2Health News:Grass Roots Wellness Initiative Builds Muscle in Jackson, Tennessee 3Health News:Grass Roots Wellness Initiative Builds Muscle in Jackson, Tennessee 4Health News:Beyond OCD Support Group Marks Fifth Anniversary 2Health News:EnvirOasis Lighting Announces Energy Star and Design Lights Consortium LED Products 2Health News:People With Borderline Personality Disorder May Misinterpret Facial Emotions 2Health News:People With Borderline Personality Disorder May Misinterpret Facial Emotions 3Health News:Shortage of Key Drug Hampering U.S. Efforts to Control TB: Report 2
... asks board member to seek restatement of Beth ... Massbank director Allan,Bufferd should apply the same ... companies to his role on the board of ... group 1199 SEIU United,Healthcare Workers East. Bufferd is ...
... Bulletin Board: GXYF), a leading developer and marketer of,cheese ... today announced that it will host an investor conference ... the 2008 fiscal year at,11:00 a.m. EST on Friday, ... results before the market opens the same day., ...
... board member to seek restatement of Beth Israel Deaconess,Medical ... CEO and,director Robert Lepofsky should apply the same Sarbanes-Oxley ... his role as Vice,Chairperson of the board of CareGroup, ... according to labor group 1199 SEIU,United Healthcare Workers East., ...
... Sodium and salt levels in foods and,beverages are on ... food,and beverage industry. Why? In two words -- health concerns. ... or No Sodium or Salt,Foods and Beverages in the U.S., ... foodservice menu items and beverages. All of,which have been argued ...
... is also available in German . , ... are childless against their will. The microscopic procedure significantly improves ... was discovered by scientists at the University of Bonn together ... of 124 women. Up to now, the desire to have ...
... markets strong, ADA, Mich., Feb. 6 Alticor ... $7.1 billion for the year ended Dec. 31,2007, a ... Company officials attributed the increase to continued growth ... America, a rebound in,China following the long-awaited establishment of ...
Cached Medicine News:Health News:Massbank Board Member Should Use Sarbanes-Oxley Disclosure Rules in Non-Profit Role, Asserts 1199 SEIU 2Health News:Galaxy Nutritional Foods Announces Third Quarter FY2008 Earnings Conference Call for Friday, February 8, 2008 2Health News:Brooks Automation Executive and Board Member Should Use Sarbanes-Oxley Disclosure Rules in Non-Profit Role, Asserts 1199 SEIU 2Health News:Sodium Content Foods and Beverages Gain Revenues as Americans are Embracing Low- and No-Sodium Campaigns 2Health News:Significantly higher success rates with artificial insemination 2Health News:Alticor's 2007 Global Sales Top $7 Billion 2Health News:Alticor's 2007 Global Sales Top $7 Billion 3Health News:Alticor's 2007 Global Sales Top $7 Billion 4Health News:Alticor's 2007 Global Sales Top $7 Billion 5Health News:Alticor's 2007 Global Sales Top $7 Billion 6
... adjusted for perfect focus where it's needed ... This, along with Keeler's wide angle light ... the patient's pupil size, you will see ... Lithium-ion technology provides a longer life battery ...
... adjusted for perfect focus where it's needed ... This, along with Keeler's wide angle light ... the patient's pupil size, you will see ... Lithium-ion technology provides a longer life battery ...
... Ophthalmoscope with superior aspherical optics. The separation ... of the aspherical optical system avoids corneal ... allows you to view the whole of ... with a small pupil. Conventional ophthalmoscopes often ...
... with superior aspherical optics. The separation of ... the aspherical optical system avoids corneal and ... you to view the whole of the ... a small pupil. Conventional ophthalmoscopes often let ...
Medicine Products: